Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.

Takuya Yamashita,Masaki Shiota,Asako Machidori,Satoshi Kobayashi,T. Matsumoto,Keisuke Monji,Eiji Kashiwagi,Ario Takeuchi,Ryosuke Takahashi,Junichi Inokuchi,Kenichiro Shiga,Akira Yokomizo,Masatoshi Eto

Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.

2021

Takuya Yamashita
Masaki Shiota
Asako Machidori
Satoshi Kobayashi
T. Matsumoto
Keisuke Monji
Eiji Kashiwagi
Ario Takeuchi
Ryosuke Takahashi
Junichi Inokuchi
Kenichiro Shiga
Akira Yokomizo
Masatoshi Eto

We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) betwee...

Keywords:

treatment failure
castration resistant
Docetaxel
Internal medicine
Regimen
Adverse effect
Chemotherapy
Oncology
Prostate cancer
Treatment Schedule
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations